Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01208766
Registration number
NCT01208766
Ethics application status
Date submitted
23/09/2010
Date registered
24/09/2010
Date last updated
21/08/2024
Titles & IDs
Public title
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Query!
Scientific title
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Query!
Secondary ID [1]
0
0
2009-017903-28
Query!
Secondary ID [2]
0
0
HOVON 95 MM
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
HO95
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bortezomib, Melphalan, Prednisone (VMP)
Treatment: Drugs - 1 or 2 cycle(s) HDM (High Dose Melphalan)
Treatment: Drugs - 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
Active comparator: R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP) - All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
Experimental: R1: 1 (2) cycle(s) HDM - All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
No intervention: R2: none - No consolidation, patients will continue to Lenalidomide maintenance.
Experimental: R2: 2 cycles of VRD - In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
Treatment: Drugs: Bortezomib, Melphalan, Prednisone (VMP)
* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32
* Melphalan _ 9 mg/m² _ p.o. _ days 1-4
* Prednisone _ 60 mg/m² _ p.o. _ days 1-4
Treatment: Drugs: 1 or 2 cycle(s) HDM (High Dose Melphalan)
- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2\*
\*Patients with renal insufficiency 100 mg/m2 only at day -3
If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.
Treatment: Drugs: 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11
* Lenalidomide _ 25 mg _ p.o. _ days 1-21
* Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).
Query!
Assessment method [1]
0
0
For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).
Query!
Timepoint [1]
0
0
end of trial (last patient last visit)
Query!
Primary outcome [2]
0
0
For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first
Query!
Assessment method [2]
0
0
For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first
Query!
Timepoint [2]
0
0
end of trial (last patient last visit)
Query!
Primary outcome [3]
0
0
For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first
Query!
Assessment method [3]
0
0
For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first
Query!
Timepoint [3]
0
0
end of trial (last patient last visit)
Query!
Secondary outcome [1]
0
0
Overall survival measured from the time of registration /randomization R1/ randomization R2. Patients still alive or lost to follow up are censored at the date they were last known to be alive.
Query!
Assessment method [1]
0
0
Overall survival measured from the time of registration /randomization R1/ randomization R2.
Patients still alive or lost to follow up are censored at the date they were last known to be alive.
Query!
Timepoint [1]
0
0
end of trial (last patient last visit)
Query!
Secondary outcome [2]
0
0
Toxicity
Query!
Assessment method [2]
0
0
Toxicity
Query!
Timepoint [2]
0
0
End of trial (last patient last visit)
Query!
Secondary outcome [3]
0
0
Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.
Query!
Assessment method [3]
0
0
Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.
Query!
Timepoint [3]
0
0
end of trial (last patient last visit)
Query!
Eligibility
Key inclusion criteria
* Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III according to the International Staging System ISS (see appendix A), i.e. at least one of the CRAB criteria should be present;
* Measurable disease as defined by the presence of M-protein in serum or urine (serum M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain ratio;
* Age 18-65 years inclusive;
* WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by comorbid conditions);
* Negative pregnancy test at inclusion if applicable;
* Written informed consent.
Inclusion for randomisation 1:
* WHO performance 0-2;
* Bilirubin and transaminases < 2.5 times the upper limit of normal values;
* A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to national guidelines).
Inclusion for randomisation 2:
* Bilirubin and transaminases < 2.5 times the upper limit of normal values;
* ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l;
* Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention Risk Management Plan.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Known intolerance of Boron;
* Systemic AL amyloidosis;
* Primary Plasmacell Leukemia;
* Non-secretory MM;
* Previous chemotherapy or radiotherapy except local radiotherapy in case of local myeloma progression or corticosteroids maximum 5 days for symptom control;
* Severe cardiac dysfunction (NYHA classification II-IV);
* Significant hepatic dysfunction, unless related to myeloma;
* Patients with GFR <15 ml/min,
* Patients known to be HIV-positive;
* Patients with active, uncontrolled infections;
* Patients with neuropathy, CTC grade 2 or higher;
* Patients with a history of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma;
* Patients who are not willing or capable to use adequate contraception during the therapy (all men, all pre-menopausal women);
* Lactating women.
Exclusion for randomisation 1:
* Severe pulmonary, neurologic, or psychiatric disease;
* CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;
* Allogeneic Stem Cell Transplantation (Allo SCT) planned;
* Progressive disease.'
Exclusion for randomisation 2:
* Progressive disease;
* Neuropathy, except CTCAE grade 1;
* CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/01/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1503
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
AU-Brisbane-PAH - Brisbane
Query!
Recruitment hospital [2]
0
0
AU-Canberra-CANBERRAHOSPITAL - Canberra
Query!
Recruitment hospital [3]
0
0
AU-Melbourne-ALFRED - Melbourne
Query!
Recruitment hospital [4]
0
0
AU-Sydney-CONCORD - Sydney
Query!
Recruitment hospital [5]
0
0
AU-Sydney-NEPEAN - Sydney
Query!
Recruitment hospital [6]
0
0
Prince of Wales Hospital - Sydney
Query!
Recruitment hospital [7]
0
0
St George Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Brisbane
Query!
Recruitment postcode(s) [2]
0
0
- Canberra
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment postcode(s) [4]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Linz
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Salzburg
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Vienna
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Antwerpen
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Haine-Saint-Paul
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
La Louvière
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Liège
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Mons
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Roeselare
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Saint-Ghislain
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Tournai
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Turnhout
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Brno
Query!
Country [14]
0
0
Czechia
Query!
State/province [14]
0
0
Hradec
Query!
Country [15]
0
0
Czechia
Query!
State/province [15]
0
0
Olomouc
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Ostrava
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Plzen
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Prague
Query!
Country [19]
0
0
Denmark
Query!
State/province [19]
0
0
Aalborg
Query!
Country [20]
0
0
Denmark
Query!
State/province [20]
0
0
Aarhus
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Copenhagen
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
Herlev
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Odense
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Roskilde
Query!
Country [25]
0
0
Finland
Query!
State/province [25]
0
0
Turku
Query!
Country [26]
0
0
Greece
Query!
State/province [26]
0
0
Athens
Query!
Country [27]
0
0
Hungary
Query!
State/province [27]
0
0
Budapest
Query!
Country [28]
0
0
Hungary
Query!
State/province [28]
0
0
Szeged
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
Alessandria
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Ancona
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Ascoli Piceno
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Avellino
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Bari
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Bergamo
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Bologna
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Bolzano
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Brescia
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Brindisi
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Cagliari
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Candiolo
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Catania
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Cosenza
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Cuneo
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Foggia
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Gallarate
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Genova
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Latina
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Lecco
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Marche
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Meldola
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Messina
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Mestre
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Milano
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Modena
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Napoli
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Novara
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Nuoro
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Orbassano
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Padova
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Palermo
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Pavia
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Perugia
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Pesaro
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Pescara
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Ravenna
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Reggio Calabria
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Reggio Emilia
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rimini
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Rionero In Vulture
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Roma
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Rozzano
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Siena
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Taranto
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Terni
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Torino
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Tricase
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Trieste
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Udine
Query!
Country [79]
0
0
Luxembourg
Query!
State/province [79]
0
0
Luxembourg
Query!
Country [80]
0
0
Netherlands
Query!
State/province [80]
0
0
Alkmaar
Query!
Country [81]
0
0
Netherlands
Query!
State/province [81]
0
0
Almere
Query!
Country [82]
0
0
Netherlands
Query!
State/province [82]
0
0
Amersfoort
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Amstelveen
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Amsterdam
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Apeldoorn
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Arnhem
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Assen
Query!
Country [88]
0
0
Netherlands
Query!
State/province [88]
0
0
Beverwijk
Query!
Country [89]
0
0
Netherlands
Query!
State/province [89]
0
0
Breda
Query!
Country [90]
0
0
Netherlands
Query!
State/province [90]
0
0
Capelle Aan Den IJssel
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Delft
Query!
Country [92]
0
0
Netherlands
Query!
State/province [92]
0
0
Den Bosch
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Den Haag
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
Deventer
Query!
Country [95]
0
0
Netherlands
Query!
State/province [95]
0
0
Dirksland
Query!
Country [96]
0
0
Netherlands
Query!
State/province [96]
0
0
Doetinchem
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Dordrecht
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Drachten
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Ede
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Eindhoven
Query!
Country [101]
0
0
Netherlands
Query!
State/province [101]
0
0
Emmen
Query!
Country [102]
0
0
Netherlands
Query!
State/province [102]
0
0
Enschede
Query!
Country [103]
0
0
Netherlands
Query!
State/province [103]
0
0
Geldrop
Query!
Country [104]
0
0
Netherlands
Query!
State/province [104]
0
0
Goes
Query!
Country [105]
0
0
Netherlands
Query!
State/province [105]
0
0
Gorinchem
Query!
Country [106]
0
0
Netherlands
Query!
State/province [106]
0
0
Gouda
Query!
Country [107]
0
0
Netherlands
Query!
State/province [107]
0
0
Groningen
Query!
Country [108]
0
0
Netherlands
Query!
State/province [108]
0
0
Heerlen
Query!
Country [109]
0
0
Netherlands
Query!
State/province [109]
0
0
Helmond
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Hilversum
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Hoofddorp
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Hoorn
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Leeuwarden
Query!
Country [114]
0
0
Netherlands
Query!
State/province [114]
0
0
Leiden
Query!
Country [115]
0
0
Netherlands
Query!
State/province [115]
0
0
Maastricht
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Nieuwegein
Query!
Country [117]
0
0
Netherlands
Query!
State/province [117]
0
0
Nijmegen
Query!
Country [118]
0
0
Netherlands
Query!
State/province [118]
0
0
Roermond
Query!
Country [119]
0
0
Netherlands
Query!
State/province [119]
0
0
Roosendaal
Query!
Country [120]
0
0
Netherlands
Query!
State/province [120]
0
0
Rotterdam
Query!
Country [121]
0
0
Netherlands
Query!
State/province [121]
0
0
Sittard
Query!
Country [122]
0
0
Netherlands
Query!
State/province [122]
0
0
Spijkenisse
Query!
Country [123]
0
0
Netherlands
Query!
State/province [123]
0
0
Terneuzen
Query!
Country [124]
0
0
Netherlands
Query!
State/province [124]
0
0
Tilburg
Query!
Country [125]
0
0
Netherlands
Query!
State/province [125]
0
0
Utrecht
Query!
Country [126]
0
0
Netherlands
Query!
State/province [126]
0
0
Venlo
Query!
Country [127]
0
0
Netherlands
Query!
State/province [127]
0
0
Winterswijk
Query!
Country [128]
0
0
Netherlands
Query!
State/province [128]
0
0
Zwolle
Query!
Country [129]
0
0
Norway
Query!
State/province [129]
0
0
Bergen
Query!
Country [130]
0
0
Norway
Query!
State/province [130]
0
0
Førde
Query!
Country [131]
0
0
Norway
Query!
State/province [131]
0
0
Harstad
Query!
Country [132]
0
0
Norway
Query!
State/province [132]
0
0
Kristiansand
Query!
Country [133]
0
0
Norway
Query!
State/province [133]
0
0
Levanger
Query!
Country [134]
0
0
Norway
Query!
State/province [134]
0
0
Lørenskog
Query!
Country [135]
0
0
Norway
Query!
State/province [135]
0
0
Oslo
Query!
Country [136]
0
0
Norway
Query!
State/province [136]
0
0
Sandvika
Query!
Country [137]
0
0
Norway
Query!
State/province [137]
0
0
Stavanger
Query!
Country [138]
0
0
Norway
Query!
State/province [138]
0
0
Tromsø
Query!
Country [139]
0
0
Norway
Query!
State/province [139]
0
0
Trondheim
Query!
Country [140]
0
0
Norway
Query!
State/province [140]
0
0
Ålesund
Query!
Country [141]
0
0
Portugal
Query!
State/province [141]
0
0
Lisboa
Query!
Country [142]
0
0
Sweden
Query!
State/province [142]
0
0
Borås
Query!
Country [143]
0
0
Sweden
Query!
State/province [143]
0
0
Eskilstuna
Query!
Country [144]
0
0
Sweden
Query!
State/province [144]
0
0
Falun
Query!
Country [145]
0
0
Sweden
Query!
State/province [145]
0
0
Göteborg
Query!
Country [146]
0
0
Sweden
Query!
State/province [146]
0
0
Halmstad
Query!
Country [147]
0
0
Sweden
Query!
State/province [147]
0
0
Helsingborg
Query!
Country [148]
0
0
Sweden
Query!
State/province [148]
0
0
Jönköping
Query!
Country [149]
0
0
Sweden
Query!
State/province [149]
0
0
Lidkoping
Query!
Country [150]
0
0
Sweden
Query!
State/province [150]
0
0
Linköping
Query!
Country [151]
0
0
Sweden
Query!
State/province [151]
0
0
Luleå
Query!
Country [152]
0
0
Sweden
Query!
State/province [152]
0
0
Lund
Query!
Country [153]
0
0
Sweden
Query!
State/province [153]
0
0
Stockholm
Query!
Country [154]
0
0
Sweden
Query!
State/province [154]
0
0
Sundsvall
Query!
Country [155]
0
0
Sweden
Query!
State/province [155]
0
0
Uddevalla
Query!
Country [156]
0
0
Sweden
Query!
State/province [156]
0
0
Umeå
Query!
Country [157]
0
0
Sweden
Query!
State/province [157]
0
0
Uppsala
Query!
Country [158]
0
0
Sweden
Query!
State/province [158]
0
0
Växjö
Query!
Country [159]
0
0
Sweden
Query!
State/province [159]
0
0
Örebro
Query!
Country [160]
0
0
Switzerland
Query!
State/province [160]
0
0
Aarau
Query!
Country [161]
0
0
Switzerland
Query!
State/province [161]
0
0
Basel
Query!
Country [162]
0
0
Switzerland
Query!
State/province [162]
0
0
Bellinzona
Query!
Country [163]
0
0
Switzerland
Query!
State/province [163]
0
0
Bern
Query!
Country [164]
0
0
Switzerland
Query!
State/province [164]
0
0
Chur
Query!
Country [165]
0
0
Switzerland
Query!
State/province [165]
0
0
Geneve
Query!
Country [166]
0
0
Switzerland
Query!
State/province [166]
0
0
Liestal
Query!
Country [167]
0
0
Switzerland
Query!
State/province [167]
0
0
Luzern
Query!
Country [168]
0
0
Switzerland
Query!
State/province [168]
0
0
Saint Gallen
Query!
Country [169]
0
0
Switzerland
Query!
State/province [169]
0
0
Zürich
Query!
Country [170]
0
0
Turkey
Query!
State/province [170]
0
0
Adana
Query!
Country [171]
0
0
Turkey
Query!
State/province [171]
0
0
Ankara
Query!
Country [172]
0
0
Turkey
Query!
State/province [172]
0
0
Istanbul
Query!
Country [173]
0
0
Turkey
Query!
State/province [173]
0
0
Izmir
Query!
Country [174]
0
0
Turkey
Query!
State/province [174]
0
0
Kayseri
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Stichting Hemato-Oncologie voor Volwassenen Nederland
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Stichting European Myeloma Network
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Gruppo Italiano Malattie EMatologiche dell'Adulto
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
DSMM (Deutsche Studiengruppe Multiples Myelom)
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
NMSG (Nordic Myeloma Study Group)
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Central European Myeloma Study Group
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study phase: phase III Study objective: * Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT) * Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation * Comparison of single versus tandem high dose Melphalan with ASCT Patient population: Patients with symptomatic multiple myeloma,previously untreated, ISS stages 1-3, age 18-65 years inclusive Study design: Prospective, multicenter, intergroup, randomized Duration of treatment: Expected duration of induction, stem cell collection and intensification is 6 - 9 months. Consolidation with VRD will last 2 months Maintenance therapy with Lenalidomide will be given until relapse. All patients will be followed until 10 years after registration.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01208766
Query!
Trial related presentations / publications
Schmitz A, Brondum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frolund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bodker JS, Roug AS, Bogsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkaer K. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Erratum In: Lancet Haematol. 2020 Jun;7(6):e443. doi: 10.1016/S2352-3026(20)30146-0. Lancet Haematol. 2020 Nov;7(11):e785. doi: 10.1016/S2352-3026(20)30330-6. Gambella M, Omede P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pieter Sonneveld, Prof.
Query!
Address
0
0
Stichting Hemato-Oncologie voor Volwassenen Nederland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01208766
Download to PDF